These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1012 related items for PubMed ID: 19700948

  • 1. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC, Shiovitz TM, Tariot PN, Porsteinsson AP, Baker KD, Feldman PD.
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [Abstract] [Full Text] [Related]

  • 3. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.
    Neurology; 2007 Jul 31; 69(5):459-69. PubMed ID: 17664405
    [Abstract] [Full Text] [Related]

  • 4. Galantamine treatment of vascular dementia: a randomized trial.
    Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C, GAL-INT-26 Study Group.
    Neurology; 2007 Jul 31; 69(5):448-58. PubMed ID: 17664404
    [Abstract] [Full Text] [Related]

  • 5. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK.
    Neurology; 2009 May 05; 72(18):1555-61. PubMed ID: 19176895
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, Donepezil MSAD Study Investigators Group.
    Int J Geriatr Psychiatry; 2005 Jun 05; 20(6):559-69. PubMed ID: 15920715
    [Abstract] [Full Text] [Related]

  • 7. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J.
    Arch Neurol; 2006 Oct 05; 63(10):1402-8. PubMed ID: 17030655
    [Abstract] [Full Text] [Related]

  • 8. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
    Chappell AS, Gonzales C, Williams J, Witte MM, Mohs RC, Sperling R.
    Neurology; 2007 Mar 27; 68(13):1008-12. PubMed ID: 17389305
    [Abstract] [Full Text] [Related]

  • 9. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
    Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C.
    Arch Neurol; 2005 May 27; 62(5):753-7. PubMed ID: 15883262
    [Abstract] [Full Text] [Related]

  • 10. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug 01; 32(6):1538-44. PubMed ID: 18573585
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Antuono PG.
    Arch Intern Med; 1995 Sep 11; 155(16):1766-72. PubMed ID: 7654110
    [Abstract] [Full Text] [Related]

  • 12. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men.
    Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, Reback E, Porter V, Swerdloff R, Cummings JL.
    Arch Neurol; 2006 Feb 11; 63(2):177-85. PubMed ID: 16344336
    [Abstract] [Full Text] [Related]

  • 13. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R.
    N Engl J Med; 2004 Dec 09; 351(24):2509-18. PubMed ID: 15590953
    [Abstract] [Full Text] [Related]

  • 14. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
    Dubois B, McKeith I, Orgogozo JM, Collins O, Meulien D.
    Int J Geriatr Psychiatry; 1999 Nov 09; 14(11):973-82. PubMed ID: 10556869
    [Abstract] [Full Text] [Related]

  • 15. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R.
    Methods Find Exp Clin Pharmacol; 1999 Nov 09; 21(9):633-44. PubMed ID: 10669911
    [Abstract] [Full Text] [Related]

  • 16. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW, Yik PY, Mok W, Chung CP.
    Int J Clin Pract; 2007 Mar 09; 61(3):403-10. PubMed ID: 17313606
    [Abstract] [Full Text] [Related]

  • 17. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
    Canal N, Imbimbo BP.
    Clin Pharmacol Ther; 1996 Aug 09; 60(2):218-28. PubMed ID: 8823240
    [Abstract] [Full Text] [Related]

  • 18. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
    Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H, LEADe investigators.
    Alzheimers Dement; 2008 Mar 09; 4(2):145-53. PubMed ID: 18631958
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
    Gutzmann H, Kühl KP, Hadler D, Rapp MA.
    Pharmacopsychiatry; 2002 Jan 09; 35(1):12-8. PubMed ID: 11819153
    [Abstract] [Full Text] [Related]

  • 20. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N, Ott BR, Peskind E, Resnick EM.
    Alzheimer Dis Assoc Disord; 2007 Jan 09; 21(1):60-4. PubMed ID: 17334274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.